Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE PuraMed BioScience, Inc.
SCHOFIELD, Wis., June 3, 2014 /PRNewswire/ -- PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that Patricia McMurtrie will hold the positions of COO, President, and Director, effective May 27, 2014. In this role, Ms. McMurtrie will be responsible for the oversight of day-to-day business functions as well as key product development and distribution functions.
"I'm pleased to welcome Patricia to the PuraMed team," said Russ Mitchell Chairman and Chief Executive Officer of PuraMed BioScience. "Patricia has an intimate knowledge of the company and our products. I believe that her presence will support and drive PuraMed's continued growth and prosperity as we move forward."
"I am excited to be part of the PuraMed BioScience team," said McMurtrie. "I've seen LipiGesic® M, a natural migraine pain reliever, make a difference in the lives of people in my personal circle. It is extremely rewarding to be a part of a company that can change people's lives for the better. I look forward to the development and distribution of additional products that are just as effective in the lives of others."
Ms. McMurtrie brings over twenty years of varied business experience relative to the marketing and communications field. As co-owner and marketing director for Envision Marketing & Design, LLC, since 2001, Patricia has extensive experience working with many clients from a variety of industries. This knowledge will be valuable as she plays a key role in the development of future strategic plans.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch additional cannabinoid enhanced anti-inflammatory and anxiolytic products as it moves forward in the development of its CBD product line.
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
©2012 PR Newswire. All Rights Reserved.